GlaxoSmithKline
NEWS
Venture capital firm SR One, founded in 1985 as the venture capital arm of pharma giant GlaxoSmithKline, completed its spinout from its parent company and closed its first independent fun at $500 million.
It was a moderately busy week for clinical trial news. Here’s a look.
In the October 2 verdict, Circuit Judge Pauline Newman said that promotional materials, press releases, product catalogs, FDA labels and witness testimony did support the “induced infringement” judgement against Teva.
The new approval makes it the first FDA-approved therapy in over a decade to treat HES and the third indication for the therapy overall.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
GlaxoSmithKline’s Trelegy Ellipta won regulatory approval for the treatment of asthma in patients aged 18 years and older. Here’s what you need to learn.
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
When Moncef Slaoui was tapped to helm Operation Warp Speed, he sought confirmation that politics would not play a role in driving certain treatments through an approval process without the proper supporting scientific data to back it up.
JOBS
IN THE PRESS